Boston Scientific Corporation BSX
NYSE · Healthcare · Medical - Devices
$41.98
Close on Fri, 20 Nov 2026 · market value $60.8B
What the price is betting on
Below its recordAt $42, the price assumes revenue grows about 0.6% a year for five years, from $21.1B to about $21.6B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 7.6% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than BSX? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$42
Base
$48
Bull
$53
Today $42
- Bear $42. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $48. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $53. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$21.1B$21B, on the path
- FY2027$21.2B$20.8B, on the path
- FY2028$21.4B$21.9B, on the path
- FY2029$21.5B$23.2B, on the path
- FY2030$21.6B$25.6B, on the path
Each year's revenue at 0.6% growth from $21.1B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Devices · listed on NYSE
- Revenue, FY2025
- $20.1B
- Growth, 3 years a year
- 15%
- Cash margin
- 18%
- Net debt
- $10.4B
- Shares, 3-year change
- +3.8%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.